606 related articles for article (PubMed ID: 30937839)
41. Molecular mechanisms regulating NLRP3 inflammasome activation.
Jo EK; Kim JK; Shin DM; Sasakawa C
Cell Mol Immunol; 2016 Mar; 13(2):148-59. PubMed ID: 26549800
[TBL] [Abstract][Full Text] [Related]
42. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.
Alcocer-Gómez E; Casas-Barquero N; Williams MR; Romero-Guillena SL; Cañadas-Lozano D; Bullón P; Sánchez-Alcazar JA; Navarro-Pando JM; Cordero MD
Pharmacol Res; 2017 Jul; 121():114-121. PubMed ID: 28465217
[TBL] [Abstract][Full Text] [Related]
43. The Nlrp3 inflammasome: contributions to intestinal homeostasis.
Zaki MH; Lamkanfi M; Kanneganti TD
Trends Immunol; 2011 Apr; 32(4):171-9. PubMed ID: 21388882
[TBL] [Abstract][Full Text] [Related]
44. NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis.
Luan J; Zhang X; Wang S; Li Y; Fan J; Chen W; Zai W; Wang S; Wang Y; Chen M; Meng G; Ju D
Front Immunol; 2018; 9():758. PubMed ID: 29692782
[TBL] [Abstract][Full Text] [Related]
45. NLRP3 inflammasome in colitis and colitis-associated colorectal cancer.
Perera AP; Sajnani K; Dickinson J; Eri R; Körner H
Mamm Genome; 2018 Dec; 29(11-12):817-830. PubMed ID: 30206651
[TBL] [Abstract][Full Text] [Related]
46. NLRP3 inflammasome: a promising target in ischemic stroke.
Gao L; Dong Q; Song Z; Shen F; Shi J; Li Y
Inflamm Res; 2017 Jan; 66(1):17-24. PubMed ID: 27576327
[TBL] [Abstract][Full Text] [Related]
47. The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases.
Wang D; Duncan B; Li X; Shi J
J Dermatol Sci; 2020 Jun; 98(3):146-151. PubMed ID: 32173167
[TBL] [Abstract][Full Text] [Related]
48. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome.
Neudecker V; Haneklaus M; Jensen O; Khailova L; Masterson JC; Tye H; Biette K; Jedlicka P; Brodsky KS; Gerich ME; Mack M; Robertson AAB; Cooper MA; Furuta GT; Dinarello CA; O'Neill LA; Eltzschig HK; Masters SL; McNamee EN
J Exp Med; 2017 Jun; 214(6):1737-1752. PubMed ID: 28487310
[TBL] [Abstract][Full Text] [Related]
49. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation.
Sun Y; Zhao Y; Yao J; Zhao L; Wu Z; Wang Y; Pan D; Miao H; Guo Q; Lu N
Biochem Pharmacol; 2015 Mar; 94(2):142-54. PubMed ID: 25677765
[TBL] [Abstract][Full Text] [Related]
50. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
51. SIRT1 inhibits inflammatory response partly through regulation of NLRP3 inflammasome in vascular endothelial cells.
Li Y; Wang P; Yang X; Wang W; Zhang J; He Y; Zhang W; Jing T; Wang B; Lin R
Mol Immunol; 2016 Sep; 77():148-56. PubMed ID: 27505710
[TBL] [Abstract][Full Text] [Related]
52. Differential role of the NLRP3 inflammasome in infection and tumorigenesis.
Tartey S; Kanneganti TD
Immunology; 2019 Apr; 156(4):329-338. PubMed ID: 30666624
[TBL] [Abstract][Full Text] [Related]
53. Identification of WT161 as a Potent Agent for the Treatment of Colitis by Targeting the Nucleotide-Binding Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome.
Long X; Yu X; Gong P; Wang X; Tian L
Front Pharmacol; 2022; 13():780179. PubMed ID: 35330829
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
[TBL] [Abstract][Full Text] [Related]
55. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys.
Yaribeygi H; Katsiki N; Butler AE; Sahebkar A
Drug Discov Today; 2019 Jan; 24(1):256-262. PubMed ID: 30086405
[TBL] [Abstract][Full Text] [Related]
56. An IBD-associated pathobiont synergises with NSAID to promote colitis which is blocked by NLRP3 inflammasome and Caspase-8 inhibitors.
Singh R; Rossini V; Stockdale SR; Saiz-Gonzalo G; Hanrahan N; D' Souza T; Clooney A; Draper LA; Hill C; Nally K; Shanahan F; Andersson-Engels S; Melgar S
Gut Microbes; 2023; 15(1):2163838. PubMed ID: 36656595
[TBL] [Abstract][Full Text] [Related]
57. Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation.
Cosin-Roger J; Simmen S; Melhem H; Atrott K; Frey-Wagner I; Hausmann M; de Vallière C; Spalinger MR; Spielmann P; Wenger RH; Zeitz J; Vavricka SR; Rogler G; Ruiz PA
Nat Commun; 2017 Jul; 8(1):98. PubMed ID: 28740109
[TBL] [Abstract][Full Text] [Related]
58. Role of inflammasomes in intestinal inflammation and Crohn's disease.
Opipari A; Franchi L
Inflamm Bowel Dis; 2015 Jan; 21(1):173-81. PubMed ID: 25517598
[TBL] [Abstract][Full Text] [Related]
59. GPCRs in NLRP3 Inflammasome Activation, Regulation, and Therapeutics.
Tang T; Gong T; Jiang W; Zhou R
Trends Pharmacol Sci; 2018 Sep; 39(9):798-811. PubMed ID: 30054020
[TBL] [Abstract][Full Text] [Related]
60. Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential.
Su M; Wang W; Liu F; Li H
Curr Med Chem; 2021; 28(3):569-582. PubMed ID: 31971103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
